EUVIMEDEUVIMED entdecken
Open Access

Clinical and Molecular Characteristics of Patients With Young-Onset and Average-Onset Pancreatic Adenocarcinoma

Adriana C Gamboa iD, Kever A Lewis iD, Laura R Prakash iD, Zhouxuan Li, Wei Qiao iD, Dan Zhao iD, Mark W Hurd iD, Mahmoud Yousef iD, Naruhiko Ikoma, Michael P Kim iD, Jeffrey E Lee iD, Jessica E Maxwell und 3 weitere

JCO Precision Oncology · 2026

DOI: 10.1200/po-25-00703 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2026. Verfasst von Adriana C Gamboa und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Adenocarcinoma. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE The incidence of young-onset pancreatic cancer (YO-PC) has risen over the past two decades, yet its molecular characteristics and long-term outcomes remain poorly defined. METHODS We retrospectively evaluated patients with PC treated at a tertiary referral center from 2016 to 2022 who had available molecular data. Patients were classified as YO-PC (≤50 years) or average-onset PC (AO-PC, >50 years). A subset analysis examined outcomes in those who underwent curative-intent pancreatectomy. Primary end points included overall survival (OS) and recurrence-free survival (RFS). RESULTS Among 511 patients, 10.9% had YO-PC (n = 56; median age 44 years). Patients with YO-PC more commonly self-identified as non-White compared with patients with AO-PC (41.1% v 26.4%, P = .03). BMI, anatomic stage, and CA19-9 level at presentation were similar between groups. KRAS mutations were the most prevalent somatic alterations in both the YO-PC and AO-PC cohorts (87.0% v 88.0%, P = .83), followed by TP53 (73.5% v 74.1%, P = .93), CDKN2A (14.6% v . 23.6%, P = .20), and SMAD4 (18.2% v 12.9%, P = .34). KRAS -specific allele subtypes were also similar ( P = .38). A subset analysis in the surgical cohort (n = 167) yielded similar results. OS was similar for YO-PC and AO-PC (18.7 v 21.7 months; P = .29). In the surgical cohort, OS and RFS for YO-PC and AO-PC were also similar (OS, 31.2 v 47.1 months, P = .34; RFS, 10.3 v 14.7 months, P = .10). CONCLUSION In this single-institution study, patients with YO-PC and AO-PC demonstrated similar clinicopathologic and molecular profiles; however, the study population to date may be underpowered. Routine molecular testing on all patients diagnosed with PC will be critical to better understand its clinical and molecular heterogeneity and to inform design of practice-changing clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsAdenocarcinomaHumansMaleRetrospective StudiesFemaleMiddle AgedAdultAge of OnsetProto-Oncogene Proteins p21(ras)Mutation

Substanzen

Proto-Oncogene Proteins p21(ras)

Autor:innen und Institutionen

  • Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Ahmed Center for Pancreatic Cancer Research, University of Texas MD Anderson Cancer Center, Houston, TX.
  • Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX.

ORCID-Profile: Adriana C Gamboa, Kever A Lewis, Laura R Prakash, Wei Qiao, Dan Zhao, Mark W Hurd, Mahmoud Yousef, Michael P Kim, Jeffrey E Lee, Ching-Wei D Tzeng, Matthew H G Katz, Rebecca A Snyder

Förderung

  • NCI NIH HHS

Zitieren

APA

Gamboa, A. C., Lewis, K. A., Prakash, L. R., Li, Z., Qiao, W., Zhao, D., Hurd, M. W., Yousef, M., Ikoma, N., Kim, M. P., Lee, J. E., Maxwell, J. E., Tzeng, C. D., Katz, M. H. G., & Snyder, R. A. (2026). Clinical and Molecular Characteristics of Patients With Young-Onset and Average-Onset Pancreatic Adenocarcinoma. JCO Precision Oncology. https://doi.org/10.1200/po-25-00703

Vancouver

Gamboa AC, Lewis KA, Prakash LR, Li Z, Qiao W, Zhao D, et al. Clinical and Molecular Characteristics of Patients With Young-Onset and Average-Onset Pancreatic Adenocarcinoma. JCO Precision Oncology. 2026. doi:10.1200/po-25-00703

BibTeX
@article{Gamboa2026,
  author = {Gamboa, Adriana C and Lewis, Kever A and Prakash, Laura R and Li, Zhouxuan and Qiao, Wei and Zhao, Dan and Hurd, Mark W and Yousef, Mahmoud and Ikoma, Naruhiko and Kim, Michael P and Lee, Jeffrey E and Maxwell, Jessica E and Tzeng, Ching-Wei D and Katz, Matthew H G and Snyder, Rebecca A},
  title = {Clinical and Molecular Characteristics of Patients With Young-Onset and Average-Onset Pancreatic Adenocarcinoma},
  journal = {JCO Precision Oncology},
  year = {2026},
  doi = {10.1200/po-25-00703}
}
Kostenlos starten →